Amgen Launches AmgenNow for Direct Access to Repatha
Today, Amgen has unveiled a remarkable consumer initiative known as AmgenNow, designed to elevate patient access to Repatha (evolocumab), a treatment proven to significantly reduce the risk of major adverse cardiovascular events. This program offers a substantial discount, which is nearly 60% off the current list price, enabling eligible patients to acquire Repatha for only $239 monthly.
Empowering Patients with Affordable Medication
AmgenNow is a groundbreaking step in ensuring that more patients can obtain necessary medications, especially those who are uninsured or face high deductibles. The program welcomes everyone who might prefer to pay out of pocket. With this pricing, Amgen solidifies its commitment to making healthcare accessible, ensuring that American patients have a beneficial pathway to important treatments.
A Commitment to Healthcare Affordability
Murdo Gordon, Amgen's executive vice president of Global Commercial Operations, emphasizes the company's dedication to enhancing patient care. "Over five million patients have already benefited from Repatha," he stated. Going a step further, the AmgenNow program aims to simplify the process for uninsured patients or those who choose to self-pay, in turn allowing a greater number of individuals at risk of major cardiovascular events to access this effective treatment.
Accessibility for All Patients Nationwide
Starting from today, all patients using Repatha will have access to AmgenNow, regardless of their participation in government programs like Medicare or Medicaid. This initiative liberates patients from the constraints often tied to insurance requirements, such as step therapy or prior authorization, which can delay treatment.
A Revolutionary Step in Drug Distribution
Additionally, AmgenNow will soon be made available through the TrumpRx website, further expanding its reach. This direct-to-patient model represents a significant shift in how medications like Repatha are distributed, reflecting the evolving nature of pharmaceutical care and accessibility.
Understanding Repatha and Its Benefits
Repatha is a monoclonal antibody that plays a critical role in combating hypercholesterolemia and associated cardiovascular risks. By inhibiting the action of proprotein convertase subtilisin/kexin type 9 (PCSK9), Repatha enhances the liver's ability to clear low-density lipoprotein (LDL) cholesterol from the blood, which is pivotal in lowering bad cholesterol levels and thereby reducing cardiovascular threats. Over the past 15 years, its safety and efficacy have been validated through numerous clinical trials involving more than 57,000 patients.
Global Approval and Indications for Repatha
Repatha is approved in over 74 countries, including the United States and member nations of the European Union. It is specifically indicated for individuals at increased risk for serious cardiovascular events, assisting in lowering LDL cholesterol levels whether they are adults with hypercholesterolemia or pediatric patients with familial hypercholesterolemia (HeFH or HoFH).
Safety Information for Patients
While Repatha presents a robust solution for cholesterol management, patients should be aware of possible hypersensitivity reactions and be cautious if they have a history of serious reactions to the medication. Common side effects reported include nasopharyngitis, upper respiratory infections, and possible injection site reactions, although these effects are generally manageable and reversible.
Amgen's Ongoing Commitment to Innovation
With over four decades of experience in biopharmaceutical innovation, Amgen continues to be at the forefront of scientific advancements. The company not only discovers and develops medicines but also manufactures and delivers new therapies that address some of the most challenging diseases faced globally.
Acknowledgments and Recognitions
Recently, Amgen was acknowledged as one of the "World's Most Innovative Companies" by Fast Company, showcasing various accolades that highlight its contributions to healthcare. As a leading player on the Nasdaq-100 Index and part of the Dow Jones Industrial Average, Amgen exemplifies growth and commitment to patients worldwide.
Frequently Asked Questions
What is the purpose of the AmgenNow program?
The AmgenNow program aims to make Repatha more accessible and affordable for patients, significantly reducing the medication's cost.
Who is eligible for the AmgenNow program?
All Repatha patients, including those who are uninsured or on high-deductible plans, can benefit from the AmgenNow program.
How much does Repatha cost through AmgenNow?
Repatha will be offered through AmgenNow at a significantly reduced monthly price of $239.
How does Repatha work?
Repatha helps lower bad cholesterol by inhibiting PCSK9, which allows more LDL receptors in the liver to clear LDL cholesterol from the bloodstream.
Where can I learn more about Amgen's offerings?
For additional information regarding Amgen's products and programs, you may visit Amgen.com.
